588 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
3 Tech Stocks for Growth Investors to Buy Right Now http://www.zacks.com/stock/news/406067/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-ZC-FT-406067 Apr 30, 2019 - Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...
Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut http://www.zacks.com/stock/news/406076/lilly-lly-down-despite-q1-earnings-beat-on-sales-view-cut?cid=CS-ZC-FT-406076 Apr 30, 2019 - Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.
Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y http://www.zacks.com/stock/news/405929/incyte-incy-q1-earnings-revenues-beat-estimates-up-y-y?cid=CS-ZC-FT-405929 Apr 30, 2019 - While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.
Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice http://www.zacks.com/stock/news/404799/looking-for-a-growth-stock-3-reasons-why-lilly-lly-is-a-solid-choice?cid=CS-ZC-FT-404799 Apr 29, 2019 - Lilly (LLY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates http://www.zacks.com/stock/news/405274/5-drug-biotech-stocks-poised-to-beat-q1-earnings-estimates?cid=CS-ZC-FT-405274 Apr 28, 2019 - So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/404479/astrazenecas-azn-q1-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-404479 Apr 26, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.
Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales http://www.zacks.com/stock/news/404335/sanofi-sny-q1-earnings-top-genzyme-vaccines-drive-sales?cid=CS-ZC-FT-404335 Apr 26, 2019 - Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.
Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/403595/bayer-bayry-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-403595 Apr 25, 2019 - Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Top Stock Reports for Eli Lilly, Altria & Becton Dickinson http://www.zacks.com/research-daily/376965/top-stock-reports-for-eli-lilly-altria-becton-dickinson?cid=CS-ZC-FT-376965 Apr 10, 2019 - Top Stock Reports for Eli Lilly, Altria & Becton Dickinson

Pages: 123456789...59

<<<Page 4>